Strategy for Transitioning Off an Insulin Pump

Initial Assessment and Planning

The American Diabetes Association recommends discussing alternative insulin delivery methods, focusing on multiple daily injections as the primary alternative to pump therapy, before discontinuing pump therapy 3, 4
Ensure the patient has all necessary supplies for MDI therapy before disconnecting the pump, as suggested by the American Association of Clinical Endocrinologists 2

The British Journal of Anaesthesia guidelines suggest calculating the total daily basal insulin dose from the pump and replacing it with long-acting insulin in divided doses, while maintaining the same insulin-to-carbohydrate ratios for mealtime boluses 1, 2
Replace the 24-hour basal dose with an equivalent subcutaneous injection of long-acting insulin (glargine or detemir) in 2 divided doses 12 hours apart, as recommended by the American College of Endocrinology 1, 2
Administer the first injection of long-acting insulin while the pump is still active, to prevent gaps in insulin coverage, according to the British Journal of Anaesthesia 1
Discontinue the insulin pump 2 hours after the first injection of basal insulin to ensure adequate insulin coverage, as suggested by the American Association of Clinical Endocrinologists 1, 2

Check blood glucose 2 hours after transitioning and do not go to bed until blood glucose is in target range, as recommended by the British Journal of Anaesthesia 1
Increase blood glucose monitoring frequency during the first 48-72 hours after transition, according to the American Diabetes Association 3, 4
Monitor for signs of hyperglycemia (blood glucose >14 mmol/L or >250 mg/dL) and check for ketones if hyperglycemia occurs, as suggested by the British Journal of Anaesthesia 1

For patients with type 1 diabetes, the transition requires particularly careful monitoring due to absolute insulin deficiency, as recommended by the American Diabetes Association 3, 4
Consider temporary use of intravenous insulin if transitioning during acute illness or hospitalization, according to The Lancet Diabetes and Endocrinology 5

Risk of diabetic ketoacidosis (DKA) during transition: Ensure no gaps in insulin coverage by overlapping pump and injection therapies, as suggested by the American Association of Clinical Endocrinologists 2
Risk of hypoglycemia: Start with 80-90% of the calculated basal dose if concerned about hypoglycemia risk, according to the American Association of Clinical Endocrinologists 2
Difficulty with injection technique: Provide education on proper injection technique, including site rotation and needle selection, as recommended by the American Diabetes Association 4

Blood glucose consistently >14 mmol/L (>250 mg/dL) despite correction boluses, as recommended by the British Journal of Anaesthesia 1
Presence of ketones in blood or urine, according to the British Journal of Anaesthesia 1
Symptoms of DKA (nausea, vomiting, abdominal pain, fruity breath), as suggested by the American Association of Clinical Endocrinologists 2
Severe or recurrent hypoglycemia, according to the American Association of Clinical Endocrinologists 2